Page 11«..10111213..2030..»

Bavarian Nordic Upgrades its Financial Guidance for 2024

Posted: September 27, 2024 at 2:51 am

COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) upgrades its financial guidance for 2024.

More here:
Bavarian Nordic Upgrades its Financial Guidance for 2024

Posted in Global News Feed | Comments Off on Bavarian Nordic Upgrades its Financial Guidance for 2024

Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines

Posted: September 27, 2024 at 2:51 am

COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced an agreement with UNICEF for the supply of 1 million doses of the MVA-BN® mpox vaccine for countries in Africa impacted by the mpox outbreak.

Read the original post:
Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines

Posted in Global News Feed | Comments Off on Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines

OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update

Posted: September 27, 2024 at 2:51 am

OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update

More here:
OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update

Posted in Global News Feed | Comments Off on OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update

Culture Biosciences Appoints Chris Williams as Chief Executive Officer

Posted: September 27, 2024 at 2:51 am

Former COO of Cytek Biosciences brings extensive bioprocessing experience to drive next phase of growth at Culture Biosciences Former COO of Cytek Biosciences brings extensive bioprocessing experience to drive next phase of growth at Culture Biosciences

Follow this link:
Culture Biosciences Appoints Chris Williams as Chief Executive Officer

Posted in Global News Feed | Comments Off on Culture Biosciences Appoints Chris Williams as Chief Executive Officer

Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome

Posted: September 27, 2024 at 2:51 am

MNV-201 is a mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria

Read the original post:
Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome

Posted in Global News Feed | Comments Off on Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome

FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials

Posted: September 27, 2024 at 2:51 am

REDWOOD CITY, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on Biomea’s ongoing Phase I/II clinical trials of the Company’s investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively.

See more here:
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials

Posted in Global News Feed | Comments Off on FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Posted: September 27, 2024 at 2:51 am

Company Announcement

Continue reading here:
Grant of Restricted Stock Units and Warrants to Employees in Genmab

Posted in Global News Feed | Comments Off on Grant of Restricted Stock Units and Warrants to Employees in Genmab

Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30

Posted: September 27, 2024 at 2:51 am

CAMBRIDGE, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that its stockholders voted to approve the previously announced proposed sale of the Company’s VOWST business to Société des Produits Nestlé S.A. Seres will file a Current Report on Form 8-K with the SEC which details the voting results. The transaction is expected to close on September 30, 2024, subject to the satisfaction of customary closing conditions.

Here is the original post:
Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30

Posted in Global News Feed | Comments Off on Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30

Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing…

Posted: September 27, 2024 at 2:51 am

Company to host conference call today at 4:30 p.m. ET Company to host conference call today at 4:30 p.m. ET

See original here:
Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing...

Posted in Global News Feed | Comments Off on Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing…

NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M

Posted: September 27, 2024 at 2:51 am

TORONTO and HAIFA, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company developing exosome-based therapies for the multi-billion dollar regenerative medicinei market, is pleased to announce a non-brokered private placement of up to 3,636,363 units (“Units”) at a price of $0.55 per Unit for aggregate gross proceeds of up to $2,000,000 (the “Offering”) and will, on acceptance of the TSX Venture Exchange (“TSXV”), close on a first tranche of the Offering for gross proceeds of $1,610,147.55. The Company intends to use the proceeds of the Offering for working capital purposes.

Here is the original post:
NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M

Posted in Global News Feed | Comments Off on NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M

Page 11«..10111213..2030..»